Publications

Journal Article Ahead of print

PubMed: 42340413 DOI: 10.1007/s00392-026-02973-9

Real-world characteristics and management of ventricular tachycardias in ICD patients: Data from the VIDEO registry.

Clin Res Cardiol

Authors: Fabienne Kreimer, Julian Wolfes, Thomas Riemer, Jochen Senges, Christian Perings, Roland Tilz, Ibrahim Akin, Christian Meyer, Thomas Kleemann, Malte Kuniss, Daniel Steven, Lars Eckardt

Affiliations

  • Department for Cardiology II: Electrophysiology, University Hospital Münster, Klinik Für Kardiologie II: Rhythmologie, Albert-Schweitzer-Campus 1 Gebäude A1, 48149, Münster, Germany.
  • Department for Cardiology II: Electrophysiology, University Hospital Münster, Klinik Für Kardiologie II: Rhythmologie, Albert-Schweitzer-Campus 1 Gebäude A1, 48149, Münster, Germany.
  • Stiftung Institut Für Herzinfarktforschung (IHF), Ludwigshafen, Germany.
  • Department of Cardiology and Electrophysiology, St. Marien Hospital Lünen, Lünen, Germany.
  • Department of Cardiac Electrophysiology, University Hospital Schleswig-Holstein-Campus Lübeck, Lübeck, Germany.
  • Department of Cardiology and Electrophysiology, University Hospital Mannheim, Mannheim, Germany.
  • Departement of Cardiology, Angiology, Intensive Care, cNEP Research Consortium EVK, Düsseldorf, Germany.
  • Department of Cardiology and Electrophysiology, Klinikum Ludwigshafen, Ludwigshafen, Germany.
  • Department of Cardiology and Electrophysiology, Herzzentrum Kerckhoff-Klinik Bad Nauheim, Bad Nauheim, Germany.
  • Department of Electrophysiology, University Hospital Köln, Cologne, Germany.

Abstract

BACKGROUND

While VT ablation is increasingly recognized as effective, its real-world efficacy, risks, and outcomes require further investigation. This study aims to assess VT ablations in a real-world scenario using data from the German VIDEO registry.

METHODS

We analyzed 801 ICD patients hospitalized with VT within the German VIDEO registry between 2018 and 2023. Among these, 145 patients (18%) underwent VT ablation. Characteristics and in-hospital outcomes were compared between patients with and without ablation.

RESULTS

Patients (mean age 63 ± 14 years, 19% female) selected for VT ablation had fewer comorbidities. The ablation group had lower rates of diabetes mellitus (16.6% vs. 24.7%, p = 0.04), chronic kidney disease (11.0% vs. 25.0%, p < 0.01), and ischemic heart disease (55.9% vs. 68.1%, p < 0.01). In-hospital outcomes differed between groups, with fewer ICU admissions (39.3% vs. 55.5%, p < 0.01) and less need for mechanical ventilation (11.0% vs. 20.1%, p = 0.01) in the ablation group. Additionally, the ablation group experienced fewer serious arrhythmic events, including lower rates of ventricular fibrillation (8.3% vs. 17.2%, p < 0.01) and cardiac arrest (9.7% vs. 19.1%, p < 0.01) while in-hospital mortality did not differ significantly.

CONCLUSION

In this real-world registry, about 20% of VT patients underwent catheter ablation. Patients undergoing ablation had fewer comorbidities, indicating substantial selection. Observed differences in in-hospital outcomes likely reflect the combination of patient selection for ablation and treatment effects.

MeSH

Diabetes Mellitus, Registries, Tachycardia, Ventricular, Comorbidity, Heart Diseases, Hospital Mortality, Tachycardia